ZA201001427B - Compositions of humanized notch fusion proteins and methods of treatment - Google Patents

Compositions of humanized notch fusion proteins and methods of treatment

Info

Publication number
ZA201001427B
ZA201001427B ZA2010/01427A ZA201001427A ZA201001427B ZA 201001427 B ZA201001427 B ZA 201001427B ZA 2010/01427 A ZA2010/01427 A ZA 2010/01427A ZA 201001427 A ZA201001427 A ZA 201001427A ZA 201001427 B ZA201001427 B ZA 201001427B
Authority
ZA
South Africa
Prior art keywords
compositions
treatment
methods
fusion proteins
notch fusion
Prior art date
Application number
ZA2010/01427A
Other languages
English (en)
Inventor
Carrie Shawber
Jan Kitajewski
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of ZA201001427B publication Critical patent/ZA201001427B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
ZA2010/01427A 2007-08-23 2010-02-26 Compositions of humanized notch fusion proteins and methods of treatment ZA201001427B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96605207P 2007-08-23 2007-08-23
PCT/US2008/010045 WO2009025867A2 (en) 2007-08-23 2008-08-22 Compositions of humanized notch fusion proteins and methods of treatment

Publications (1)

Publication Number Publication Date
ZA201001427B true ZA201001427B (en) 2011-05-25

Family

ID=40378882

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/01427A ZA201001427B (en) 2007-08-23 2010-02-26 Compositions of humanized notch fusion proteins and methods of treatment

Country Status (15)

Country Link
US (2) US9127085B2 (enExample)
EP (1) EP2193143B1 (enExample)
JP (2) JP2010536855A (enExample)
KR (1) KR20100076947A (enExample)
CN (1) CN101883786A (enExample)
AU (1) AU2008289462B2 (enExample)
BR (1) BRPI0815291A2 (enExample)
CA (1) CA2697262A1 (enExample)
IL (2) IL204111A (enExample)
MX (1) MX2010002053A (enExample)
NZ (3) NZ600171A (enExample)
RU (1) RU2532830C2 (enExample)
SG (1) SG183763A1 (enExample)
WO (1) WO2009025867A2 (enExample)
ZA (1) ZA201001427B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US9567396B2 (en) 2006-03-07 2017-02-14 Evonik Degussa Gmbh Notch inhibition in the prevention of vein graft failure
US8133857B2 (en) 2006-03-07 2012-03-13 The Brigham and Women's FHospital, Inc. NOTCH inhibition in the treatment of atherosclerosis
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
EP2262890A1 (en) * 2008-02-22 2010-12-22 Vrije Universiteit Brussel Method for generating islet beta cells from dedifferentiated exocrine pancreatic cells
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
MX2011000233A (es) 2008-07-08 2011-05-19 Oncomed Pharm Inc Agentes de union del receptor notch1 y metodos para su uso.
SG193873A1 (en) * 2008-08-22 2013-10-30 Univ Columbia Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
CN102958534B (zh) 2010-01-13 2014-11-05 昂考梅德药品有限公司 Notch1结合剂及其使用方法
TW201329105A (zh) * 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物
ES2744267T3 (es) 2012-11-21 2020-02-24 Pharmabcine Inc Anticuerpo de doble diana que se dirige a VEGFR-2 y DLL4, y composición farmacéutica que comprende el mismo
WO2014141064A1 (en) 2013-03-13 2014-09-18 Novartis Ag Notch2 binding molecules for treating respiratory diseases
US20160030513A1 (en) * 2013-03-15 2016-02-04 The Trustees Of Columbia University In The City Of New York Notch1 Decoy Antagonists Protect From Obesity-Induced Insulin Resistance and Fatty Liver
WO2014151950A1 (en) * 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Notch1 decoy antagonists protect from obesity-induced insulin resistance and fatty liver
AR104250A1 (es) * 2015-04-16 2017-07-05 Eisai R&D Man Co Ltd Anticuerpo anti-notch4 humano
US11026996B2 (en) 2016-05-25 2021-06-08 The Trustees Of Columbia University In The City Of New York Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
US11325957B2 (en) * 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
AU2018370002B2 (en) 2017-11-16 2025-08-07 The Regents Of The University Of California Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof
CN108753833B (zh) * 2018-05-28 2021-12-03 上海海洋大学 斑马鱼notch3基因突变体的制备方法
CN108707628B (zh) * 2018-05-28 2021-11-23 上海海洋大学 斑马鱼notch2基因突变体的制备方法
CN109467598B (zh) * 2018-11-28 2021-11-09 生命谷（海南）生物科技股份有限公司 肿瘤相关基因notch1突变短肽及其应用
WO2021202381A2 (en) * 2020-03-30 2021-10-07 Memorial Sloan Kettering Cancer Center Methods and compositions for modulating lipid storage in adipose tissue
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
CN114062682A (zh) * 2021-11-10 2022-02-18 厦门大学附属心血管病医院 Notch3作为检测靶标的应用
CN116790603B (zh) * 2023-08-18 2023-10-31 成都中科奥格生物科技有限公司 一种sgRNA、CRISPR/Cas9载体及其构建方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
FR2751986B1 (fr) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
GB9623236D0 (en) * 1996-11-07 1997-01-08 Imperial College Notch
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
JP2005526701A (ja) * 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
WO2003087159A2 (en) * 2002-04-05 2003-10-23 Lorantis Limited Modulators of the notch signalling pathway and uses thereof in medical treatment
JP2006513260A (ja) 2002-08-03 2006-04-20 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路調節因子の複合体およびその薬物治療への使用
WO2004024764A1 (en) * 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
WO2006047878A1 (en) 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
KR20080025761A (ko) * 2005-07-29 2008-03-21 더 제너럴 하스피탈 코포레이션 피부 손상을 감소시키는 방법 및 조성물
CA2666672A1 (en) 2006-10-19 2008-05-02 Genentech, Inc. Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
SG193873A1 (en) 2008-08-22 2013-10-30 Univ Columbia Human notch3 based fusion proteins as decoy inhibitors of notch3 signaling
TW201329105A (zh) 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物

Also Published As

Publication number Publication date
US20160115217A1 (en) 2016-04-28
EP2193143A4 (en) 2012-01-25
AU2008289462A1 (en) 2009-02-26
NZ618129A (en) 2015-05-29
NZ600171A (en) 2014-01-31
KR20100076947A (ko) 2010-07-06
MX2010002053A (es) 2010-07-28
IL220723A0 (en) 2012-08-30
JP2016040245A (ja) 2016-03-24
NZ583649A (en) 2012-06-29
US20110008342A1 (en) 2011-01-13
IL204111A (en) 2015-08-31
CA2697262A1 (en) 2009-02-26
BRPI0815291A2 (pt) 2015-02-03
EP2193143A2 (en) 2010-06-09
SG183763A1 (en) 2012-09-27
JP2010536855A (ja) 2010-12-02
RU2532830C2 (ru) 2014-11-10
WO2009025867A3 (en) 2009-12-30
RU2010110812A (ru) 2011-09-27
AU2008289462B2 (en) 2014-01-23
US9127085B2 (en) 2015-09-08
CN101883786A (zh) 2010-11-10
EP2193143B1 (en) 2016-06-08
WO2009025867A2 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
IL220723A0 (en) Compositions of humanized notch fusion proteins and methods of treatment
IL262205A (en) Protein formulations and methods for their preparation
ZA200805743B (en) Compositions and methods of use for antibodies of Dickkopf-1 and/or -4
IL202573A0 (en) Methods and compositions for treating allergic diseases
ZA201008952B (en) Compositions and methods of use for therapeutic antibodies
IL206978A0 (en) Powdered protein compositions and methods of making same
HUE046564T2 (hu) XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra
GB201108374D0 (en) Compositions and methods for the treatment of altered synuclein function
EP2104513A4 (en) OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE
ZA201107551B (en) Compositions and methods for antibodies targeting complement protein c3b
PL3208612T3 (pl) Kompozycje i sposoby leczenia chorób o podłożu immunologicznym
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
EP2185719A4 (en) RANTES ANTIBODIES AND METHOD FOR THEIR USE
PT2046128E (pt) Composição herbicida e seu método de utilização
SI2046118T1 (sl) Herbicidni sestavki in postopek njihove uporabe
HK1140778A (en) Compositions of humanized notch fusion proteins and methods of treatment
ZA200900543B (en) Compositions and methods for the treatment of mucormycosis and other fungal diseases
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
GB0814580D0 (en) herbicidal composition and method of use thereof
GB0814582D0 (en) Herbicidal composition and method of use thereof
GB0814583D0 (en) Herbicidal composition and method of use thereof
IL199793A0 (en) Anti-bacterial peptides and methods of treating diseases using same
IL207858A0 (en) Immunoglobulin compositions and methods of producing same
GB0814581D0 (en) Herbicidal composition and method of use thereof